Last Updated : November 10, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | ||
Tecentriq | Atezolizumab | Withdrawn | ||||
Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecfidera | Dimethyl fumarate | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Technivie | Ombitasvir/ paritaprevir/ ritonavir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete | ||
Teveten Plus | Eprosartan mesylate/ hydrochlorothiazide | Hypertension, Essential | List in a similar manner to other drugs in class | Complete | ||
Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Tibsovo | ivosidenib | Acute myeloid leukemia (AML) | Reimburse with clinical criteria and/or conditions | Active | ||
Tivicay | Dolutegravir | HIV infection | List | Complete | ||
Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | ||
Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Translarna | ataluren | Cancelled | ||||
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete |